KLAR.ST
Klaria Pharma Holding AB (publ.) [KLAR.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
KLAR.ST Stock Summary
Top 10 Correlated ETFs
KLAR.ST
Top 10 Correlated Stocks
KLAR.ST
In the News
KLAR.ST Financial details
Company Rating
-
Market Cap
17.52M
Income
-35.78M
Revenue
7.15M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
5
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-1.39
Forward P/E
-
PEG
0.2
P/S
5.29
P/B
1.08
P/C
-
P/FCF
-1.7
Quick Ratio
0.09
Current Ratio
0.19
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.35
EPS next Y
-
EPS next Q
-
EPS this Y
-67.27%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-12.94%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-11.1%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-52%
ROE
-61%
ROC
-0.65%
Gross Margin
100%
Oper. Margin
-351%
Profit Margin
-419%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.15-0.78
52W High
-
52W Low
-
RSI
25
Rel Volume
0.75
Avg Volume
253.46K
Volume
190.19K
Perf Week
-8.97%
Perf Month
-61.33%
Perf Quarter
-
Perf Half Y
27.67%
-
-
-
-
Beta
0.302
-
-
Volatility
0.01%, 0.25%
Prev Close
-7.31%
Price
0.406
Change
-0.73%
Company Profile
- Volume Average 253.46K
- Market Capitalization 17.52M
- Employee 5
- CEO Mr. Scott Boyer
- Headquarters Uppsala,SE
- IPO Date 2015-10-21
-
Website
https://www.klaria.com 
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company in Sweden and internationally. It offers Sumatriptan for the treatment of migraine; and Midazolam for acute epilepsy. The company's clinical phase products include Epinephrine/Adrenaline for the treatment of acute allergic reaction; Naloxone for opioid overdose; and Ketamine for acute pain and depression. It also focuses on the commercialization of cannabis/cannabinoids, including THC and CBD for medical and recreational applications. The company was founded in 2014 and is based in Uppsala, Sweden.
